Mhrs_restrictive formulary jan12.xls
Restrictive Formulary
RESTRICTIVE PMB FORMULARY
Effective 1 Jan 2012
Products included on this chronic medicines formulary wil not attract a co-payment if authorised by Chronic Medicine Management for a disease on the CDL and obtained from the Designated Service Provider.
Reimbursement will
however be subject to the Chronic Medicine Management clinical guidelines and protocols and the Medicine Price List (MPL).
KEY to Chronic Medicine Management Reimbursement Criteria:Quantity/dosage and duration of authorisation may vary - depending on the requested drug. Accepted Treatment - wil be authorised without requesting additional clinical information (unless specific concerns e.g. unusual dose requests).
Clinical Review - wil be authorised if the drug history or co-morbidity clearly indicates that use of the drug is indicated in the specific patient.
Clinical Motivation - specific clinical information required before reimbursement is considered
Specialist Script - wil require a relevant specialist's prescription before reimbursement is considered
Specialist Motivation - wil require a relevant specialist motivation before reimbursement is considered
Special Investigations (SI) - results of recent relevant tests required before reimbursement is considered
Drug Name
Active Ingredient
Strength
Chronic Medicine Management Reimbursement Criteria for
formulary drugs
Asthma Inhaled B2 agonists AIROMIR INHALER
Long acting B2 agonists FO
Inhaled corticosteroids BECEZE INHALER COMPLETE
Restrictive Formulary
Oral Xanthines PULMOPHYLLIN SR 200
Oral Corticosteroids ADCO PREDNISOLONE
Addison's disease Oral Corticosteroids COVOCORT
Bipolar Mood Disorder Mood Stabilisers ARROW LAMOTRIGINE
Restrictive Formulary
Restrictive Formulary
Antipsychotic agents ASPEN RISPERIDONE
Accepted treatment (clinical motivation for low-cost options)
Accepted treatment (clinical motivation for low-cost options)
Accepted treatment (clinical motivation for low-cost options)
Accepted treatment (clinical motivation for low-cost options)
Accepted treatment (clinical motivation for low-cost options)
Accepted treatment (clinical motivation for low-cost options)
Accepted treatment (clinical motivation for low-cost options)
Accepted treatment (clinical motivation for low-cost options)
Accepted treatment (clinical motivation for low-cost options)
Accepted treatment (clinical motivation for low-cost options)
Accepted treatment (clinical motivation for low-cost options)
Accepted treatment (clinical motivation for low-cost options)
Accepted treatment (clinical motivation for low-cost options)
Accepted treatment (clinical motivation for low-cost options)
Accepted treatment (clinical motivation for low-cost options)
Accepted treatment (clinical motivation for low-cost options)
Accepted treatment (clinical motivation for low-cost options)
Accepted treatment (clinical motivation for low-cost options)
Accepted treatment (clinical motivation for low-cost options)
Accepted treatment (clinical motivation for low-cost options)
Accepted treatment (clinical motivation for low-cost options)
Accepted treatment (clinical motivation for low-cost options)
Accepted treatment (clinical motivation for low-cost options)
Accepted treatment (clinical motivation for low-cost options)
Accepted treatment (clinical motivation for low-cost options)
Accepted treatment (clinical motivation for low-cost options)
Accepted treatment (clinical motivation for low-cost options)
Accepted treatment (clinical motivation for low-cost options)
Accepted treatment (clinical motivation for low-cost options)
Accepted treatment (clinical motivation for low-cost options)
Accepted treatment (clinical motivation for low-cost options)
Accepted treatment (clinical motivation for low-cost options)
Accepted treatment (clinical motivation for low-cost options)
Accepted treatment (clinical motivation for low-cost options)
Accepted treatment (clinical motivation for low-cost options)
Accepted treatment (clinical motivation for low-cost options)
Accepted treatment (clinical motivation for low-cost options)
Accepted treatment (clinical motivation for low-cost options)
Accepted treatment (clinical motivation for low-cost options)
Restrictive Formulary
Accepted treatment (clinical motivation for low-cost options)
Accepted treatment (clinical motivation for low-cost options)
Accepted treatment (clinical motivation for low-cost options)
Accepted treatment (clinical motivation for low-cost options)
Accepted treatment (clinical motivation for low-cost options)
Accepted treatment (clinical motivation for low-cost options)
Accepted treatment (clinical motivation for low-cost options)
Accepted treatment (clinical motivation for low-cost options)
Accepted treatment (clinical motivation for low-cost options)
Accepted treatment (clinical motivation for low-cost options)
Accepted treatment (clinical motivation for low-cost options)
Accepted treatment (clinical motivation for low-cost options)
Accepted treatment (clinical motivation for low-cost options)
Accepted treatment (clinical motivation for low-cost options)
Accepted treatment (clinical motivation for low-cost options)
Accepted treatment (clinical motivation for low-cost options)
Accepted treatment (clinical motivation for low-cost options)
Accepted treatment (clinical motivation for low-cost options)
Accepted treatment (clinical motivation for low-cost options)
Accepted treatment (clinical motivation for low-cost options)
Accepted treatment (clinical motivation for low-cost options)
Accepted treatment (clinical motivation for low-cost options)
Accepted treatment (clinical motivation for low-cost options)
Accepted treatment (clinical motivation for low-cost options)
Accepted treatment (clinical motivation for low-cost options)
Accepted treatment (clinical motivation for low-cost options)
Antidepressants ARROW CITALOPRAM
Restrictive Formulary
Bronchiectasis
Antibiotic therapy wil be evaluated on an individual basis
Chronic Obstructive Pulmonary Disease Inhaled B2 agonists AIROMIR INHALER
Inhaled corticosteroids
Restrictive Formulary
Anticholinergic inhalers (short acting) ATROVENT 40 MAC COMPL 300 DOSE
Oral Xanthines PULMOPHYLLIN SR 200
Oral Corticosteroids CAPSOID
Restrictive Formulary
Cardiac failure/ Cardiomyopathy Anticoagulants WARFARIN
Diuretics ADCO-RETIC
Hydrochlorothiazide and potassium-sparing agents
Hydrochlorothiazide and potassium-sparing agents
Hydrochlorothiazide and potassium-sparing agents
Hydrochlorothiazide and potassium-sparing agents
Hydrochlorothiazide and potassium-sparing agents
Hydrochlorothiazide and potassium-sparing agents
Hydrochlorothiazide and potassium-sparing agents
Hydrochlorothiazide and potassium-sparing agents
Hydrochlorothiazide and potassium-sparing agents
Hydrochlorothiazide and potassium-sparing agents
Hydrochlorothiazide and potassium-sparing agents
Hydrochlorothiazide and potassium-sparing agents
Potassium supplementation PLENISH K
ACE inhibitors ACCUMAX
Restrictive Formulary
Restrictive Formulary
ACE inhibitor and diuretic combinations AURO-LISINOPRIL CO
Restrictive Formulary
Angiotensin Receptor Blockers COZAAR
Angiotensin Receptor Blockers and diuretic combinations COZAAR COMP
Beta-blockers ADCO-ATENOLOL
Restrictive Formulary
Alpha-beta blockers ASPEN CARVEDILOL
Beta-blocker and diuretic combinations ADCO-LOTEN
Cardiac glycosides LANOXIN
Restrictive Formulary
Chronic Renal Disease For diuretics and antihypertensives, refer to "Hypertension" Calcium TITRALAC
Vitamin D CALCIFEROL
Oral Iron and Folic Acid supplementation AHA FERROUS SULPHATE
Parenteral Iron Preparations COSMOFER AMPOULE 2ML
Erythropoietin ARANESP PREFILLED SYRINGE 0.3ML
Restrictive Formulary
Coronary Artery Disease Aspirin ASPIRIN (WHITE)
Nitrates ANGISED
Restrictive Formulary
Beta-blockers ADCO-ATENOLOL
Calcium channel antagonists ADALAT XL
Restrictive Formulary
Restrictive Formulary
Crohn's Disease Aminosalicylic acid preparations SALAZOPYRIN
Immunosuppressants AZAMUN
Methotrexate ABITREXATE-20ML
Steroid preparations (oral) CAPSOID
Steroid preparations (enemas) ENTOCORD ENEMAS
Diabetes Mellitus Type 1 Insulin INSU ACTRAPH HMGE 10ML VIAL
Restrictive Formulary
INSU APIDRA SOLOSTAR DISPOSABLE PENS 3ML
Applicances Diabetic strips, needles and lancets
Diabetes Mellitus Type 2 Biguanides ACCORD METFORMIN
Restrictive Formulary
Sulphonylureas ALEMBIC GLICLAZIDE
Thiazolidines ACTOS 15MG
Insulin INSU ACTRAPH HMGE 10ML VIAL
Restrictive Formulary
INSU APIDRA SOLOSTAR DISPOSABLE PENS 3ML
Applicances Diabetic strips, needles and lancets
Diabetes Insipidus
Desmopressin DDAVP
Dysrhythmias Anticoagulants WARFARIN
Antiplatelet agents ASPIRIN (WHITE)
Restrictive Formulary
Beta-blockers ADCO-ATENOLOL
Restrictive Formulary
Cardiac glycosides LANOXIN
Calcium channel antagonists CALCICARD SR
Anti-arrhythmics ARYCOR
Epilepsy ADCO-PHENOBARB VITALET ELIXIR
Restrictive Formulary
Restrictive Formulary
Restrictive Formulary
Glaucoma Sympathomimetics ALPHAGAN
Parasympathomimetics ISOPTO CARPINE 15ML
Carbonic anhydrase inhibitor AZOPTIC EYE DROP
Beta-blockers GLAUCOSAN 0.25% 5ML
Combination products COMBIGAN 2MG/5MG 5ML
Prostaglandin derivatives LUMIGAN 3ML
Acetazolamide AZOMID
Haemophilia Tranexamic Acid CYKLOKAPRON
Desmopressin DDAVP
Analgesics ACTAMOL
Restrictive Formulary
Restrictive Formulary
Hyperlipidaemia Statins ADCO-SIMVASTATIN
Restrictive Formulary
Fibrates BEZACHOLE SR
Nicotinic Acid NICOTINIC ACID
Hypertension Sympathetic Nervous System Blockers RESERPINE
Alpha-aderenergic blockers ADCO-DOXAZASIN
Arterial Vasodilators APRESOLINE
Diuretics ADCO-RETIC
Hydrochlorothiazide and potassium-sparing agents
Restrictive Formulary
Hydrochlorothiazide and potassium-sparing agents
Hydrochlorothiazide and potassium-sparing agents
Hydrochlorothiazide and potassium-sparing agents
Hydrochlorothiazide and potassium-sparing agents
Hydrochlorothiazide and potassium-sparing agents
Hydrochlorothiazide and potassium-sparing agents
Hydrochlorothiazide and potassium-sparing agents
Hydrochlorothiazide and potassium-sparing agents
Hydrochlorothiazide and potassium-sparing agents
Hydrochlorothiazide and potassium-sparing agents
Hydrochlorothiazide and potassium-sparing agents
Beta-blockers ADCO-ATENOLOL
Restrictive Formulary
Beta-blocker and diuretic combinations AD
Calcium channel antagonists ADALAT XL
Restrictive Formulary
ACE inhibitors ACCUMAX
Restrictive Formulary
Restrictive Formulary
Angiotensin Receptor Blockers
Restrictive Formulary
Angiotensin Receptor Blockers and diuretic combinations COZAAR COMP
Hypothyroidism ELTROXIN
Multiple sclerosis Anticholinergics DITROPAN
Immunosuppressants ABITREXATE-20ML
Restrictive Formulary
Muscle relaxants LIORESAL
Tricyclic Antidepressants ETHIPRAMINE
Carbamazepine DEGRANOL
Analgesics ANTALGIC 500
Restrictive Formulary
Acetylsalicylic acid comb. excl. psycholeptics
Non-steroidal anti-inflammatories AD
Restrictive Formulary
Restrictive Formulary
Parkinson's Disease Levodopa combinations CARBILEV
Dopamine agonists and other AKINETON
Restrictive Formulary
Rheumatoid arthritis Disease modifying agents ABITREXATE-20ML
Immunosuppressants AZAMUN
Alkylating agents EN
Non-steroidal anti-inflammatories ADCO-DICLOFENAC
Restrictive Formulary
Restrictive Formulary
Oral Corticosteroids ADCO PREDNISOLONE
Schizophrenia Antipsychotic agents ASPEN RISPERIDONE
Accepted treatment (clinical motivation for low-cost options)
Accepted treatment (clinical motivation for low-cost options)
Accepted treatment (clinical motivation for low-cost options)
Accepted treatment (clinical motivation for low-cost options)
Accepted treatment (clinical motivation for low-cost options)
Accepted treatment (clinical motivation for low-cost options)
Accepted treatment (clinical motivation for low-cost options)
Accepted treatment (clinical motivation for low-cost options)
Accepted treatment (clinical motivation for low-cost options)
Accepted treatment (clinical motivation for low-cost options)
Accepted treatment (clinical motivation for low-cost options)
Accepted treatment (clinical motivation for low-cost options)
Accepted treatment (clinical motivation for low-cost options)
Restrictive Formulary
Accepted treatment (clinical motivation for low-cost options)
Accepted treatment (clinical motivation for low-cost options)
Accepted treatment (clinical motivation for low-cost options)
Accepted treatment (clinical motivation for low-cost options)
Accepted treatment (clinical motivation for low-cost options)
Accepted treatment (clinical motivation for low-cost options)
Accepted treatment (clinical motivation for low-cost options)
Accepted treatment (clinical motivation for low-cost options)
Accepted treatment (clinical motivation for low-cost options)
Accepted treatment (clinical motivation for low-cost options)
Accepted treatment (clinical motivation for low-cost options)
Accepted treatment (clinical motivation for low-cost options)
Accepted treatment (clinical motivation for low-cost options)
Accepted treatment (clinical motivation for low-cost options)
Accepted treatment (clinical motivation for low-cost options)
Accepted treatment (clinical motivation for low-cost options)
Accepted treatment (clinical motivation for low-cost options)
Accepted treatment (clinical motivation for low-cost options)
Accepted treatment (clinical motivation for low-cost options)
Accepted treatment (clinical motivation for low-cost options)
Accepted treatment (clinical motivation for low-cost options)
Accepted treatment (clinical motivation for low-cost options)
Accepted treatment (clinical motivation for low-cost options)
Accepted treatment (clinical motivation for low-cost options)
Accepted treatment (clinical motivation for low-cost options)
Accepted treatment (clinical motivation for low-cost options)
Accepted treatment (clinical motivation for low-cost options)
Accepted treatment (clinical motivation for low-cost options)
Accepted treatment (clinical motivation for low-cost options)
Accepted treatment (clinical motivation for low-cost options)
Accepted treatment (clinical motivation for low-cost options)
Accepted treatment (clinical motivation for low-cost options)
Accepted treatment (clinical motivation for low-cost options)
Accepted treatment (clinical motivation for low-cost options)
Accepted treatment (clinical motivation for low-cost options)
Accepted treatment (clinical motivation for low-cost options)
Accepted treatment (clinical motivation for low-cost options)
Accepted treatment (clinical motivation for low-cost options)
Accepted treatment (clinical motivation for low-cost options)
Accepted treatment (clinical motivation for low-cost options)
Accepted treatment (clinical motivation for low-cost options)
Accepted treatment (clinical motivation for low-cost options)
Accepted treatment (clinical motivation for low-cost options)
Restrictive Formulary
Accepted treatment (clinical motivation for low-cost options)
Accepted treatment (clinical motivation for low-cost options)
Accepted treatment (clinical motivation for low-cost options)
Accepted treatment (clinical motivation for low-cost options)
Accepted treatment (clinical motivation for low-cost options)
Accepted treatment (clinical motivation for low-cost options)
Accepted treatment (clinical motivation for low-cost options)
Accepted treatment (clinical motivation for low-cost options)
Accepted treatment (clinical motivation for low-cost options)
Antidepressants ETHIPRAMINE
Mood Stabilisers ARROW LAMOTRIGINE
Restrictive Formulary
Systemic Lupus Erythematosus Non-steroidal anti-inflammatories ADCO-DICLOFENAC
Restrictive Formulary
Restrictive Formulary
Oral Corticosteroids CAP
Anticoagulants ASPIRIN (WHITE)
Disease modifying agents
Restrictive Formulary
Immunosuppressants AZAMUN
Alkylating agents ENDOXAN
Ulcerative colitis Aminosalicylic acid preparations SALAZOPYRIN
Immunosuppressants AZAMUN
Steroid preparations (oral) CAPSOID
Steroid preparations (enemas) ENTOCORD ENEMAS
Source: http://www.ungererhealth.co.za/docs/bonitas/Restrictive%20Formulary%20Jan%202012.pdf
Maria, Rina Da Bruna, Velina: storie da famea “Jan”. Un destin segnât dal fûc: chel che a furnivin al turibul da gleisia, chel che al scjaldave la int prima di lâ a Messa. Ma encje chel che ur à brusât la cjase. E che tal 1959, in Francia, al à copât Toni. Una cjasa vierta par ducj Jo pensi che ognun di nou al veibi un debit di riconossinça a famea di “Jan”, par chel
INFORME FINAL UTILIDAD DEL DIAMEL EN PACIENTES CON DIABETES MELLITUS TIPO 2 EN TRATAMIENTO COMBINADO CON GLIBENCLAMIDA Autores: Dr. José Arturo Hernández Yero* Dr. David Vargas González** *Especialista de 2do. Grado en Endocrinología, Profesor Auxiliar, Investigador Auxiliar, Vice-Director de Asistencia Médica **Residente de 3er.año en Endocrinología INTRODU
A |
B |
C |D |E |
F |
G |H |I |
J |
K |
L |
M |N |O |
P |
Q |
R |
S |
T |U |V |
W |
X |
Y |
Z |0-9 |